文献速递淋巴瘤

利妥昔单抗对儿童成熟B细胞非霍奇金淋巴瘤免疫状态的影响:Inter-B-NHL Ritux 2010试验的预设二次分析

Effect of rituximab on immune status in children with mature B-cell non-Hodgkin lymphoma: a prespecified secondary analysis of the Inter-B-NHL Ritux 2010 trial.
PubMed 文献 · Lancet Haematol · 2023-04-21

该国际开放标签随机3期试验的预设二次分析纳入421例高危成熟B细胞非霍奇金淋巴瘤患儿,比较化疗联合利妥昔单抗与单纯化疗的免疫状态。结果显示,联合利妥昔单抗组在治疗结束1个月时淋巴细胞减少、B细胞减少和低丙种球蛋白血症的发生率均更高,1年时仅低丙种球蛋白血症差异持续存在,且更常接受免疫球蛋白替代治疗。

要点

  • 治疗结束1个月时,联合利妥昔单抗组淋巴细胞减少(OR 2.92)、B细胞减少(OR 13.33)和低丙种球蛋白血症(OR 2.72)风险均高于单纯化疗组。
  • 治疗开始1年时,仅低丙种球蛋白血症差异仍存在(OR 3.64)。
  • 联合利妥昔单抗组接受免疫球蛋白替代治疗的风险更高(HR 2.63),主要因免疫球蛋白浓度低。

核心结论

  • 接受化疗联合利妥昔单抗的高危成熟B细胞非霍奇金淋巴瘤患儿存在 prolonged 低丙种球蛋白血症风险,尽管严重感染罕见。
  • 需要制定免疫球蛋白替代和再接种策略。

研究设计与样本

  • Inter-B-NHL Ritux 2010试验为国际、开放标签、随机、3期试验,纳入6个月至18岁高危成熟B细胞非霍奇金淋巴瘤患儿,比较化疗联合利妥昔单抗与单纯化疗。
  • 本分析为预设二次分析,免疫状态评估时间点为基线、治疗结束1个月、治疗开始1年及此后每年直至正常化。
  • 免疫终点评估人群为符合方案且至少一个时间点有免疫参数的合格人群;安全性评估人群为符合免疫研究条件且治疗结束后随访至少3个月无肿瘤相关事件者。
  • 2011年12月19日至2017年6月13日共纳入421例患者(男344例[82%],女77例[18%],平均年龄8.8岁[SD 4.1]),包括随机分组患者289例和计划中期分析后入组的非随机队列132例。

主要发现

  • 基线时,290例有可用数据的患者中99例(34%)存在淋巴细胞减少,368例中178例(48%)存在低丙种球蛋白血症。
  • 治疗结束1个月时,联合利妥昔单抗组较单纯化疗组更常见淋巴细胞减少(86/106[81%] vs 53/89[60%],OR 2.92[95%CI 1.53-5.57],p=0.0011)、B细胞减少(72/75[96%] vs 36/56[64%],OR 13.33[3.71-47.84],p<0.0001)和低丙种球蛋白血症(67/95[71%] vs 37/79[47%],OR 2.72[1.45-5.07],p=0.0017)。
  • 治疗开始1年时,仅低丙种球蛋白血症差异仍存在(52/94[55%] vs 16/63[25%],OR 3.64[1.81-7.31],p=0.0003)。
  • 联合利妥昔单抗组较单纯化疗组更常接受免疫球蛋白替代治疗(26/164[16%] vs 9/158[7%],HR 2.63[95%CI 1.23-5.62],p=0.010),主要因免疫球蛋白浓度低。
  • 在联合治疗组(包括非随机患者)中,对疫苗可预防感染保护性血清学丢失的比例从脊髓灰质炎的4/47(9%)到肺炎链球菌的21/50(42%)不等。

临床怎么用

  • 原文结论指出需要制定免疫球蛋白替代和再接种策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Survival of children and adolescents with high-risk, mature B-cell non-Hodgkin lymphoma is improved by the addition of rituximab to chemotherapy. The effect of rituximab on immune reconstitution after therapy has not been well described. Herein, we evaluate the immune effects of the addition of rituximab to intensive chemotherapy, a prespecified secondary aim of the Inter-B-NHL Ritux 2010 trial. METHODS: The Inter-B-NHL Ritux 2010 trial was an international, open-label, randomised, phase 3 trial in children (age 6 months to 18 years) with high-risk, mature B-cell non-Hodgkin lymphoma, comparing chemotherapy alone or chemotherapy with rituximab. Measures of immune status were completed at baseline, 1 month from the end of treatment, and 1 year from the start of therapy, and yearly thereafter until normalised. For this secondary analysis, we report on the proportions of patients with low lymphocyte counts and immunoglobulin concentrations at these timepoints with total lymphocyte count, B-cell count, and IgG concentration as the main endpoints. Other endpoints of interest included exposure to immunoglobulin replacement therapy and vaccine serologies. The population assessed for immune endpoints was the eligible per-protocol population with at least one immune parameter at one timepoint. Comparisons of immune status were made between the randomised treatment groups. Safety in the post-therapy period was assessed in the population eligible for the immunity study who were followed up at least 3 months after the end of treatment and without cancer-related events. The Inter-B-NHL Ritux 2010 study was registered with ClinicalTrials.gov, NCT01516580; status completed, with analyses of secondary aims ongoing. FINDINGS: From Dec 19, 2011, to June 13, 2017, 421 patients (344 [82%] boys and 77 [18%] girls; mean age was 8·8 years [SD 4·1]) were enrolled and had immune data at baseline during follow-up, or both. The study population included randomly assigned patients (n=289) and a non-randomised cohort enrolled after the planned interim analysis (n=132). At baseline, 99 (34%) of 290 patients with available data (excluding patients with bone marrow disease with peripheral blast cells) had lymphopenia, and 178 (48%) of 368 had hypogammaglobulinemia. 1 month from the end of therapy, patients who received chemotherapy with rituximab were more likely than those who received chemotherapy alone to have lymphopenia (86 [81%] of 106 vs 53 (60%) of 89, odds ratio [OR] 2·92 [95% CI 1·53-5·57], p=0·0011), B-cell lymphopenia (72 [96%] of 75 vs 36 [64%] of 56, OR 13·33 [3·71-47·84], p<0·0001), and hypogammaglobulinemia (67 [71%] of 95 vs 37 [47%] of 79, OR 2·72 [1·45-5·07], p=0·0017). Differences remained at 1 year for hypogammaglobulinemia only (52 [55%] of 94 vs 16 [25%] of 63, OR 3·64 [1·81-7·31], p=0·0003). Patients in the chemotherapy with rituximab group were more likely than those in the chemotherapy group to receive immunoglobulin replacement (26 [16%] 164 vs nine [7%] of 158, hazard ratio [HR] 2·63 [95% CI 1·23-5·62], p=0·010), mainly due to low immunoglobulin concentration. In the combined treatment groups, including non-randomly assigned patients, the proportion of patients who had loss of protective serologies to a vaccine preventable infection varied from four (9%) of 47 for polio to 21 (42%) of 50 for Streptococcus pneumoniae (pneumococcus). One patient (chemotherapy with rituximab group) had a life-threatening infectious event of polymicrobial bacterial sepsis reported 2 months after the final chemotherapy administration. INTERPRETATION: Children with high-risk mature B-cell non-Hodgkin lymphoma receiving chemotherapy with rituximab were at risk of prolonged hypogammaglobulinemia, although severe infections were rare. Strategies for immunoglobulin replacement and revaccination are needed. FUNDING: Clinical Research Hospital Program of the French Ministry of Health, Cancer Research UK, National Institute for Health Research Clinical Research Network in England, Children's Cancer Foundation Hong Kong, US National Cancer Institute, F Hoffmann-La Roche.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Alexander S, Aupérin A, Bomken S, et al. Effect of rituximab on immune status in children with mature B-cell non-Hodgkin lymphoma: a prespecified secondary analysis of the Inter-B-NHL Ritux 2010 trial. Lancet Haematol. 2023. PMID: 37094596. doi:10.1016/S2352-3026(23)00062-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。